Background and Objective
The pharmacokinetic disposition of ciclosporin shows great intra- and interpatient variability, and that combined with a narrow therapeutic window makes therapeutic drug monitoring of ciclosporin necessary. The nonlinear mixed-effects population pharmacokinetic program NONMEM® predicts individual pharmacokinetic parameters based not only on individual patient observations but also on population characteristics and the patient’s covariates. The aim of this model development is to potentially use it in the clinical setting to optimize ciclosporin dosing in renal transplant recipients.
A population pharmacokinetic model of ciclosporin has been developed with NONMEM® using full 12-hour pharmacokinetic profiles from 29 renal transplant recipients, 3 months of daily follow-up data from an additional 11 recipients, and both 3 months of follow-up data and full 12-hour pharmacokinetic profiles from nine patients. The internal validation of the model was based on data splitting and jack-knife methods. In addition, the model was validated for its clinical applicability on standard trough and 2-hour post-dose concentration data from 12 additional patients with 3 months of follow-up.
The model that best described the ciclosporin data was a two-compartment model with first-order absorption process with lagged time. The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V1/F) =24.4 L; absorption rate constant (ka) = 0.544 h-1; lag time =0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) =19.6 L/h. Three covariates had significant effect on a total of six pharmacokinetic parameters. These were bodyweight on V1/F and ka, time after transplantation on ka, and age on CL/F, ka and V1/F. Cytochrome P450 3A5 genotype was also a significant covariate but was not included in the final model since such information is not available in clinical practice. The external validation showed that the model was able to predict ciclosporin concentrations in the 12 new patients with an average predictive error of 17.4 ± 14% when the standard sample concentrations from the previous week were given.
A NONMEM® pharmacokinetic model for ciclosporin in renal transplant recipients was successfully developed and validated for the first 3 months post-transplantation. The model showed good predictability in a new patient cohort. After further clinical validation, the model may be applicable as a clinical tool for optimizing ciclosporin dosing in renal transplant recipients in the early post-transplant period.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789–95
Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation Neoral in organ transplantation. Drugs 2001; 61: 1957–2016
Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384–9
Hansen JM, Fogh-Andersen N, Christensen NJ, et al. Cyclosporine-induced hypertension and decline in renal function in healthy volunteers. J Hypertens 1997; 15: 319–26
Burdmann EA, Andoh TF, Yu L, et al. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465–76
Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505–11
Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903–8
Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577–83
Perner F. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148–56
Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83: 1525–35
Beal SL, Sheiner LB. NONMEM user guides. Ellicott City (MD): Icon Development Solutions, 1989–98
Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40: 375–82
Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmaco-kinetic models and design of a Bayesian estimator. Ther Drug Monit 2004; 26: 23–30
Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006; 45: 905–22
Fanta S, Jonsson S, Backman JT, et al. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007; 64: 772–84
Hesselink DA, van Gelder T, van Schaik RHN, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76(6): 545–56
Bourgoin H, Paintaud G, Buchler M, et al. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol 2005; 59: 18–27
Lukas JC, Suarez AM, Valverde MP, et al. Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. J Clin Pharm Ther 2005; 30: 549–57
Wu KH, Cui YM, Guo JF, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005; 33: 1268–75
Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007; 29: 96–102
Falck P, Åsberg A, Byberg K, et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation 2008; 86(10): 1379–83
Falck P, Asberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant recipients. Transplantation 2008; 85: 179–84
Falck P, Vethe NT, Asberg A, et al. Cinacalcet’s effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1048–53
Falck P, Guldseth H, Asberg A, et al. Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2007; 852: 345–52
Nankivell BJ, Gruenewald SM, Allen RD, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683–9
Hume R. Prediction of lean body mass from height and weight. J Clin Pathol 1966; 19: 389–91
Maitre PO, Buhrer M, Thomson D, et al. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377–84
Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4: E27
US FDA Center for Drug Evaluation and Research [CDER]. Guidance for industry: population pharmacokinetics. Rockville (MD): CDER, 1999 Feb [online]. Available from URL: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf [Accessed 2009 Jul 13]
Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264: 10388–95
Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207–13
Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–54
Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55–62
No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.
About this article
Cite this article
Falck, P., Midtvedt, K., Vân Lê Trúc, T. et al. A Population Pharmacokinetic Model of Ciclosporin Applicable for Assisting Dose Management of Kidney Transplant Recipients. Clin Pharmacokinet 48, 615–623 (2009). https://doi.org/10.2165/11313380-000000000-00000
- Pharmacokinetic Parameter
- Renal Transplant Recipient
- Absorption Rate Constant
- Objective Function Value
- Erlang Distribution